Arthneeti
Latest: Orchid Pharma Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q3 FY26 (Oct–Dec 2025).All Q3 FY26 results →
OP

Orchid Pharma Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Orchid Pharma Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹1,002
Market cap₹9.4K Cr
P/E348.0
Updated23 Aug 2026
Read4 min read

The short version

The core antibiotic market remains under pricing pressure, with a longer down cycle than usual. FY '26 remains a transition year with a weak base antibiotic market but strategic strengthening underway.

From Orchid Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The core antibiotic market remains under pricing pressure, with a longer down cycle than usual.
  • Some green shoots of recovery have been seen starting January 2026, but sustainability is unclear.
  • Differentiated products ramp-up, new geography launches, and licensing agreements are expected to gradually improve revenue mix and medium-term visibility.
  • For branded formulations, target sales of around INR 20 crores in the next year, excluding Cipla's business.
  • Hospital segment sales have stabilized with gradual month-on-month growth; a target of INR 20 crores is considered realistic for FY27.
  • Expansion of Exblifep sales is underway in Europe (Spain, Italy) and GCC regions, with ongoing global licensing discussions.

2 more points from Orchid Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Orchid Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- **7ACA Project**: Mechanical completion targeted by September 2026 with water trials expected in 1 quarter post that and commercial production following next quarter. The project is strategically critical to enhance backward integration and cost competitiveness. (Page 4, 12, 15) - **Cefiderocol Facility**: Commercial operations commissioning expected by December 2026. API production already underway, with formulation production and market launch planned post-plant readiness. (Page 7, 12) - **FDF Plant at Chennai**: Under development, expected to yield benefits for differentiated product development and long-term competitiveness. (Page 4) - **AMS Division Expansion**: Continuously scaling up with improved operating leverage and cost calibration; new product launches ongoing, including sterile and injectable formulations. (Page 4, 13) Overall, Orchid Pharma is focused on strategic investments in backward integration (7ACA), new product launches (Cefiderocol), and formulation capabilities to change its medium-term earnings profile.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Orchid Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - Advanced discussions and licensing agreements are underway for Exblifep in more than 10 countries, indicating a pipeline of potential orders beyond existing markets. - Binding and nonbinding term sheets have been signed in key geographies for Exblifep, signaling committed future business. - AMS division sales continue to increase steadily with improving operating leverage, indicating growth in ongoing orders.

2 more points from Orchid Pharma Ltd's call on order book

Create a free account to keep reading this call

Orchid Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹304 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Orchid Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Guj. Themis Bio. (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Orchid Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Orchid Pharma Ltd Q3 FY26 results?

The core antibiotic market remains under pricing pressure, with a longer down cycle than usual. FY '26 remains a transition year with a weak base antibiotic market but strategic strengthening underway.

What is Orchid Pharma Ltd share price analysis?

Orchid Pharma Ltd currently shows a neutral. The stock trades at a P/E of 348.0 with a market cap of ₹9,439 Cr. Investors should review the full earnings analysis for detailed insights.

Is Orchid Pharma Ltd planning capital expenditure?

7ACA Project: Mechanical completion targeted by September 2026 with water trials expected in 1 quarter post that and commercial production following next quarter.

Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.